MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2025 International Congress

    IncobotulinumtoxinA to Treat Sialorrhea in Parkinson’s Disease: a Real-life Study: 6-year Interim Results

    B. Bergmans, N. Winter, V. Schotte, N. Sys, E. van Massenhove, G. Pollet, H. Couckuyt, L. Delameilleure, M. van Zandijcke (Bruges, Belgium)

    Objective: We evaluate the long-term efficacy and safety of incobotulinumtoxinA injections in advanced Parkinson’s disease (PD) patients suffering from sialorrhea. Background: Sialorrhea is frequently a…
  • 2025 International Congress

    Studying the relationship between interoceptive awareness, caregiver burden, and disease perception in Parkinson’s Disease

    F. Velasco-Delgado, A. Hernandez-Medrano, E. Ramírez-Benitez, A. Cervantes-Arriaga, M. Rodríguez-Violante, D. Ulloa-Hernández, G. Martin-Mafud (Mexico City, Mexico)

    Objective: Analyze the impact of interoceptive awareness deficits on caregiver burden in Parkinson's disease. Background: Interoceptive awareness (IA) is the ability to perceive and process…
  • 2025 International Congress

    Impact of Gastrointestinal Dysfunction Symptoms on Psychomotor Recovery Following 8-Week Aerobic Interval Training in Parkinson’s Disease – Preliminary Results

    K. Lorek, K. Markowska, A. Bereza, E. Koziorowska, S. Budrewicz, P. Nowakowski, S. Chomiak (Wroclaw, Poland)

    Objective: To investigate the impact of gastrointestinal dysfunction symptoms (GIDS) on psychomotor recovery following 8-week aerobic interval training (AIT) in Parkinson's disease (PD). Background: GIDS…
  • 2025 International Congress

    Reduced Falls With ND0612: Supportive Analyses From the BouNDless Phase 3 Study

    S. Isaacson, F. Stocchi, A. Ellenbogen, N. Lopes, N. Sasson, J. Pereira, O. Rascol (Boca Raton, USA)

    Objective: Explore potential reasons for the lower rates of falls with ND0612 vs immediate-release levodopa/carbidopa (IR-LD/CD) therapy reported in the BouNDless study. Background: Falls are…
  • 2025 International Congress

    An Exercise Prescription to Slow the Progression of Parkinson’s Disease

    J. Alberts, A. Rosenfeldt, C. Lopez-Lennon, E. Jansen, C. Felix, E. Zimmerman, P. Imrey, H. Fernandez, K. Mckee, L. Dibble (Cleveland, USA)

    Objective: To evaluate the efficacy of a 12-month, home-based, high-intensity aerobic exercise intervention in slowing the progression of Parkinson’s disease (PD) using rate-focused cycling. Background:…
  • 2025 International Congress

    Caregiver Burden after DBS at GPI or STN for Parkinson’s Disease

    A. Kamath, H. Branstetter, J. Summers, T. Hassell, S. Bick, N. Banerjee, K. Dhima (Nashville, USA)

    Objective: Examine the effects of GPi or STN DBS on caregiver burden for Parkinson's Disease Background: Deep Brain Stimulation (DBS) is a common treatment used…
  • 2025 International Congress

    Enhancing Safety and Quality of Care for Parkinson’s Disease Patients Hospitalized at a Large Academic Medical Center

    C. Kim, C. Malatt, E. Hogg, E. Tan, M. Tagliati (Los Angeles, USA)

    Objective: To implement measures to improve quality of care in Parkinson's disease (PD) patients who are hospitalized at a large academic hospital with the goal…
  • 2025 International Congress

    Qualitative research in advanced Parkinson’s disease: Exploring salient symptoms and suitability of the MDS-NMS from the patient, caregiver, and clinician perspective

    N. Williamson, A. Lydon, S. Wallace, E. Taylor, M. Chaudry, H. Bradley, R. Williams-Hall, P. Boccon-Gibod, K. Raphael, E. Stevens, P. Odin, A. Antonini, M. Biagioni (Bollington, United Kingdom)

    Objective: To identify which non-motor symptoms (NMS) are most relevant in an advanced Parkinson’s Disease (PD) population and determine the suitability of the International Parkinson…
  • 2025 International Congress

    A Proof-of-Concept Study of TR-012001, a Nasal Levodopa, in Patients With Parkinson’s Disease With OFF Episodes, Without Dopa Decarboxylase Inhibitor

    M. Nomoto, H. Yabe, R. Ando, Y. Sumiyoshi, T. Akagi, R. Ise, Y. Akiyoshi, C. Date, S. Nakano, R. Suzuki, Y. Sonoda, S. Haruta, S. Kanazashi, A. Mori, I. Nagata (Tokyo, Japan)

    Objective: To evaluate the safety, tolerability, levodopa pharmacokinetics, and exploratory efficacy of TR-012001 in Parkinson’s disease (PD). Background: TR-012001 is a novel investigational prefilled nasal…
  • 2025 International Congress

    Safety, Tolerability, Pharmacokinetics And Pharmacodynamics of Vent-02, a Novel CNS-Penetrant NLRP3 Inhibitor for the Treatment of Parkinson’s Disease

    A. Matta, X. Valencia, L. Warner, K. Pike, C. Winters, L. Smidt, M. Moerland, O. Spiegelstein (Waltham, USA)

    Objective: The objectives of this first-in-human study were to assess the safety, tolerability, pharmacokinetics (PK), food-effect and pharmacodynamics of VENT-02 in healthy volunteers Background: Vent-02…
  • « Previous Page
  • 1
  • …
  • 141
  • 142
  • 143
  • 144
  • 145
  • …
  • 1734
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley